Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
May 29 AZN Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29 AZN AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
May 28 AZN Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28 AZN Cellectis Reports Financial Results for First Quarter 2024
May 28 GYRE Gyre Therapeutics announces expected addition to Russell 2000 and Russell 3000 Indexes
May 28 DVAX Dynavax to Present at Upcoming Investor Conferences
May 28 GYRE Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 28 AZN AstraZeneca, Daiichi Sankyo ADC misses key endpoint in phase 3 lung cancer trial
May 28 APGE Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28 GTLS Chart Industries to Provide Hydrogen Compression Solutions to Repsol’s Alba Project for its Sines Refinery in Portugal
May 27 APLS Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
May 27 AZN Here's Why Astrazeneca (AZN) is a Strong Growth Stock
May 27 APGE Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation
May 27 AZN AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27 AZN Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27 AZN AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial
May 27 APLS Apellis and Sobi report data from Phase II C3 glomerulopathy trial
May 26 AZN Wall Street Breakfast: The Week Ahead
May 24 APLS Apellis Pharma up on phase 2 data for kidney disease treatment pegcetacoplan
May 24 APLS Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags